Target intelligence / Profile preview

Gag polyprotein (Gag) (Gag)

Target
Gag
Molecular classification
Viral structural protein, Polyprotein
01

Overview

The Gag polyprotein is the primary structural component of retroviruses, such as the Human Immunodeficiency Virus (HIV), and is essential for the assembly, budding, and maturation of infectious progeny (UniProt P03367). Synthesized as a precursor protein (Pr55Gag), it migrates to the host cell plasma membrane where it multimerizes to drive the formation of immature viral particles (PubMed: 22534358). During or after budding, the viral protease cleaves Gag into distinct functional proteins: matrix (MA), capsid (CA), nucleocapsid (NC), and p6, along with two spacer peptides, SP1 and SP2 (NIH: PMC3415700). This proteolytic processing, particularly the final cleavage between CA and SP1, is a critical step in viral maturation that transforms the immature particle into an infectious virion. Therapeutic interventions targeting Gag include maturation inhibitors, which bind to the CA-SP1 junction to prevent cleavage, and capsid inhibitors that interfere with the stability and transport of the CA core (PubMed: 32810114). These mechanisms offer a potent means of inhibiting viral replication and are particularly valuable for treating patients with multi-drug resistant HIV strains.

Other names
Group-specific antigenPr55Gagp55Gag-Pol polyprotein precursor
02

Mechanism of action

Maturation inhibition by blocking the proteolytic cleavage of the CA-SP1 junction and modulation of capsid assembly/disassembly.

03

Biological functions

Viral assemblyViral buddingViral maturationRNA packagingHost cell membrane binding
04

Disease associations

InfectionAcquired Immunodeficiency Syndrome (AIDS)
05

Safety considerations

Rapid emergence of drug resistance mutations in the Gag SP1 regionGastrointestinal adverse effectsPotential for long-term metabolic changesInjection site reactions (for long-acting formulations like Lenacapavir)
06

Interacting drugs

Bevirimat

3 more in the full profile.

07

Biomarkers

HIV-1 RNA viral loadCD4+ T-cell countGag genotypic resistance mutations (e.g., SP1 V362I, A364V)

Beyond the preview

Go deeper on Gag polyprotein (Gag) (Gag).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gag polyprotein (Gag) (Gag).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call